/
AYTU
$2.19+$0.02 (+0.92%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$23.3M
11M shares
52-week range
$1.65 – $3.07
38% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Price (6 mo)
Loading chart…
Change$-100.21
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.7M | $7.3M | $27.6M | $65.6M | $96.7M | $107.4M | $65.2M | $66.4M |
| Cost of revenue | $2.1M | $2.2M | $8.3M | $36.4M | $46.4M | $40.8M | $16.1M | $20.6M |
| Gross profit | $1.6M | $5.1M | $19.4M | $29.2M | $50.3M | $66.6M | $49.1M | $45.8M |
| Gross margin | 44.0% | 69.9% | 70.0% | 44.5% | 52.0% | 62.0% | 75.3% | 69.0% |
| R&D | $167.6K | $589.1K | $1.7M | $5.6M | $12.7M | $4.1M | $2.8M | $1.3M |
| Operating income | −$19.7M | −$16.8M | −$21.1M | −$58.9M | −$109.9M | −$17.1M | −$1.6M | −$7.8M |
| EBITDA | −$15.3M | −$14.6M | −$12.2M | −$29.0M | −$28.0M | −$3.3M | $1.4M | −$4.7M |
| Net income | −$10.2M | −$47.2M | −$13.6M | −$58.3M | −$108.8M | −$17.1M | −$15.8M | −$13.6M |
| Net margin | -278.4% | -644.3% | -49.3% | -88.8% | -112.5% | -15.9% | -24.3% | -20.4% |
| EPS (diluted) | -3061.23 | -1210.28 | -60.20 | -69.60 | -74.01 | -5.11 | -2.86 | -2.16 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $54M | $-1.06 | $-1.08–$-1.05 | 1 |
| 2027 | $71M | $-0.08 | $-0.08–$-0.08 | 1 |
| 2028 | $94M | $1.05 | $1.04–$1.07 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
AYTU BioPharma, Inc. Common Stock
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
www.aytubio.com- Employees
- 83
- IPO / List date
- Feb 15, 2008
- HQ
- DENVER, CO
Held by traders on TradeandTell
No one on the platform currently holds AYTU.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 93,723 | $255.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2023-01-06 | 1-for-20reverse |
| 2020-12-09 | 1-for-10reverse |
| 2018-08-13 | 1-for-20reverse |
| 2017-08-29 | 1-for-20reverse |
| 2016-07-01 | 1-for-12reverse |
Recent trades on TradeandTell
No one on the platform has traded AYTU yet.
